AAX Biotech to present antibody development technologies at BIO-Europe
AAX Biotech will showcase its proprietary Opti-mAb and Seqitope platforms at the upcoming BIO-Europe conference in Cologne from November 8-11.
AAX Biotech announced its participation in the BIO-Europe partnering conference, scheduled for November 8-11 in Cologne. Business Development Manager Claudia Kielkopf will represent the firm to discuss potential partnerships regarding the company's antibody discovery and stabilization technologies.
The company plans to present two primary platforms: Opti-mAb, a linker technology designed to enhance the stability and yield of scFv-based therapeutics and CAR-T applications, and Seqitope, a high-throughput system for epitope mapping at the amino acid level.
By focusing on these technologies, the firm aims to address common challenges in early-stage antibody development, such as protein aggregation and limited performance stability. Participation in the event is intended to secure collaborative opportunities within the biopharmaceutical sector.